Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine + Carboplatin in Extensive Stage SCLC
NCT03913455Phase 2Completed
- Start
- Jun 2019
- Primary completion
- Apr 2021
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of guadecitabine in small cell lung cancer (SCLC). Primary endpoint: Progression Free Survival at 7 months. Started Jun 2019; status: completed.
02
Drugs
guadecitabine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03913455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03913455.